Stockscreener 앱 받기
11.73
0.68%
-0.10
전일 마감가:
$11.83
열려 있는:
$11.66
하루 거래량:
234.44K
Relative Volume:
0.54
시가총액:
$468.17M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+8.80%
1개월 성능:
+18.57%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$11.15
$11.79
1주일 범위
$10.23
$12.37
52주 변동 폭
$8.89
$24.36
Beta Bionics Inc Stock (BBNX) Company Profile
명칭
Beta Bionics Inc
전화
949-427-7785
주소
11 HUGHES, IRVINE
BBNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBNX
Beta Bionics Inc
|
11.76 | 468.17M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
132.27 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.56 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.51 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.41 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.33 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Beta Bionics Inc Stock (BBNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 개시 | BofA Securities | Buy |
| 2025-02-24 | 개시 | Lake Street | Buy |
| 2025-02-24 | 개시 | Leerink Partners | Outperform |
| 2025-02-24 | 개시 | Piper Sandler | Overweight |
| 2025-02-24 | 개시 | Stifel | Buy |
| 2025-02-20 | 개시 | Ladenburg Thalmann | Neutral |
| 2025-02-20 | 개시 | Robert W. Baird | Neutral |
모두보기
Beta Bionics Inc 주식(BBNX)의 최신 뉴스
Highest quarter in years as med-tech raises $8B in Q1 financings - BioWorld MedTech
Beta Bionics to Present at the Bank of America Securities Health Care Conference - The Manila Times
Midday Stock Roundup: FivePoint Rises on Earnings - Orange County Business Journal
Beta Bionics: Slowing Down Or Being Conservative? (NASDAQ:BBNX) - Seeking Alpha
Beta Bionics, Inc. (NASDAQ:BBNX) Receives $24.83 Average Target Price from Analysts - Defense World
Beta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025 - The Manila Times
Beta Bionics, Inc. to Release First Quarter 2025 Financial Results on May 6, 2025 - Nasdaq
Midday Stock Roundup: Evolus, ICU Medical down - Orange County Business Journal
Beta Bionics to Host Investor Event on June 22, 2025 - The Manila Times
CUBE LAUNCHES REGPLATFORM™ INTEL TO TRANSFORM THE MID-MARKET REGULATORY INTELLIGENCE LANDSCAPE IN FINANCIAL SERVICES - The Globe and Mail
Stifel maintains Buy rating on Beta Bionics stock, target at $25 - Investing.com Canada
SCHD ETF News, 4/2/2025 - The Globe and Mail
Beta Bionics, Inc.: Undervalued Growth Opportunity with Strategic Expansion Plans - TipRanks
Beta Bionics shares ‘too cheap’ with estimates going higher, says BofA - TipRanks
Beta Bionics Explodes to $65.1M in Revenue - Orange County Business Journal
Midday Stock Roundup: Rivian Rises - Orange County Business Journal
Newly public Beta Bionics reports sales surge; Dexcom hires CCO - MedTech Dive
Beta Bionics welcomes new board member Gerard Michel By Investing.com - Investing.com Australia
Beta Bionics appoints new board member from Delcath Systems By Investing.com - Investing.com South Africa
Beta Bionics appoints new board member from Delcath Systems - Investing.com India
Beta Bionics welcomes new board member Gerard Michel - Investing.com
Beta Bionics Appoints Gerard Michel as Director - TipRanks
Beta Bionics Announces Board Appointment of Gerard Michel - The Manila Times
Stifel maintains Buy on Beta Bionics stock, $25 price target By Investing.com - Investing.com South Africa
Piper Sandler maintains $26 target on Beta Bionics stock By Investing.com - Investing.com Australia
Piper Sandler maintains $26 target on Beta Bionics stock - Investing.com
Stifel maintains Buy on Beta Bionics stock, $25 price target - Investing.com India
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Alnylam Pharma (ALNY) and Beta Bionics, Inc. (BBNX) - The Globe and Mail
Beta Bionics Reports Strong Growth and Strategic Advances - TipRanks
Beta Bionics Inc (BBNX) Reports Q4 2024 Revenue of $20.4M and Ne - GuruFocus.com
Earnings call transcript: Beta Bionics Q4 2024 sees strong revenue growth - Investing.com Australia
Earnings call transcript: Beta Bionics Q4 2024 sees strong revenue growth By Investing.com - Investing.com South Africa
Beta Bionics stock surges as Q4 revenue more than doubles By Investing.com - Investing.com South Africa
Beta Bionics stock surges as Q4 revenue more than doubles - Investing.com Australia
Beta Bionics Inc (BBNX) 재무 분석
Beta Bionics Inc (BBNX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
10.11%
0.14%
자본화:
|
볼륨(24시간):